he prevalence of up-to-date lung cancer screening with low-dose CT (LDCT) remains low — especially in U.S. states that tend to have higher mortality rates of the disease, American Cancer Society (ACS) researchers have reported.
A team led by Priti Bandi, PhD, of the ACS in Atlanta, GA, found that overall, in 2022 only 18.1% of men and women eligible for lung cancer screening underwent it, despite a 2021 expansion of the pool of eligible individuals. It also found that lung cancer screening uptake varied across states, with a range of 9.7% to 31%. The study results were published June 10 in JAMA Internal Medicine.
We found that lung cancer screening “disparities were largest according to health care access and geographically across U.S. states, with low prevalence in southern states with high lung cancer burden,” the group noted.
See “States with higher lung cancer burden show low screening rates” (June 10, 2024)
